Skip to content
Peptide research

BPC-157

Also known as Body Protection Compound-157
Category
Tissue Repair & Recovery
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

A synthetic 15-amino-acid peptide widely used for recovery of tendons, ligaments, muscle, and the gut lining. The case rests almost entirely on animal studies. Human evidence is minimal, human safety data remain inadequate, and a theoretical tumor-growth concern (it promotes new blood-vessel formation) is unresolved. Most supply is unregulated product sold online, of uncertain purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

BPC-157 (Body Protection Compound-157) is a synthetic peptide made of 15 amino acids, originally derived from a protective protein found naturally in your stomach lining. It is one of the most widely used peptides in the wellness and recovery space, studied primarily for its ability to accelerate healing of tendons, ligaments, muscles, and gut tissue.

How it works in the body

Triggers growth of new blood vessels (angiogenesis) at injury sites by upregulating VEGF and its receptors. It also stimulates tendon cells to migrate, survive under oxidative stress, and rebuild damaged tissue. Additionally, it modulates the nitric oxide system and protects the gut lining.

Research overview

BPC-157 works primarily by stimulating the growth of new blood vessels at injury sites and activating multiple tissue repair pathways in the body. It also influences serotonin and dopamine signaling, which may explain its observed benefits for gut health and mood. One of its most distinctive properties is its remarkable stability in stomach acid — it survives for over 24 hours — which makes oral dosing a viable option, unlike most injectable peptides. Over 200 studies have been published, though the vast majority are in animals. Earlier randomized human studies exist, including a controlled ulcerative-colitis study reported in 2005.

Who researches BPC-157?

Commonly researched by

  • People exploring soft tissue recovery options

    BPC-157's primary mechanism involves angiogenesis and tissue repair signaling, making it one of the most-studied peptides for tendon, ligament, and muscle injuries.

  • People researching GI support (IBS, leaky gut, ulcers)

    Originally isolated from human gastric juice — a gastric pentadecapeptide with documented cytoprotective effects on gut lining in animal models.

  • People looking into post-surgical healing

    Animal studies show accelerated wound closure, anastomosis healing, and reduced adhesion formation across multiple surgical models.

  • People researching chronic inflammation management

    Anti-inflammatory properties documented across multiple animal models, including colitis, arthritis, and encephalomyelitis.

Important considerations for

  • Those with active cancer or a history of cancer

    High

    BPC-157 promotes angiogenesis (new blood vessel growth), which can feed tumor growth. This is its primary therapeutic mechanism repurposed by tumors.

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists. Effects on fetal development are completely unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data exists. Effects on developing systems are unknown.

  • Those with active bleeding disorders

    Moderate

    May affect blood clotting through nitric oxide system modulation. Could interact with the coagulation cascade.

Safety & interactions

Do not use if

  • Active cancer or history of cancer

    High

    BPC-157 promotes angiogenesis (new blood vessel growth), which can feed tumor growth. Avoid with any active malignancy.

  • Active bleeding disorders

    Moderate

    May affect blood clotting through nitric oxide system modulation.

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human safety data. Effects on fetal development unknown.

  • Children under 18

    Absolute

    No pediatric safety data exists.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • No large-scale human safety trials completed

    High

    No completed large trials on ClinicalTrials.gov; FDA-unapproved (DoD OPSS advisory)

  • Theoretical cancer risk (promotes angiogenesis / VEGFR2 which tumors use)

    Theoretical

    Mechanism from Hsieh et al. 2017, PMID 27847966 (VEGFR2 activation); no demonstrated tumor promotion

  • Human evidence limited to a few small, uncontrolled pilots / unpublished early-phase trials

    Low

    PL-14736 IBD Phase II (unpublished) and the n=12 interstitial-cystitis pilot

  • Named on WADA's Prohibited List since 2022

    Moderate

    WADA/USADA 2022 Prohibited List, section S0

  • Unregulated products sold online vary widely in quality

    High

    FDA / DoD OPSS advisory: BPC-157, a prohibited/unapproved peptide found in wellness products

Interaction summary(8)

Rated by direction with this peptide

  • NSAIDs (diclofenac, indomethacin, ibuprofen, aspirin as anti-inflammatory)

    ProtectiveModerate

    Across extensive rat/mouse studies BPC-157 both prevents and heals NSAID-induced gastrointestinal, liver, and brain (encephalopathy) lesions, so the relationship is gastroprotective/organoprotective. The commonly repeated 'avoid with NSAIDs due to bleeding risk' warning is not supported by the primary literature and is directionally backwards. Evidence is entirely preclinical; no human co-administration data exist.

    Diclofenac NSAID-toxicity model, Life Sci 2011, PMID 21295044; NSAID GI lesions + adjuvant arthritis, Sikiric et al., J Physiol Paris 1997

  • Anticoagulants / antiplatelets (heparin, warfarin, aspirin)

    ProtectiveTheoretical

    In rat tail-amputation models BPC-157 reduced bleeding time/hemorrhage and counteracted thrombocytopenia under heparin, warfarin, and aspirin (a hemostasis-balancing, not pro-bleeding, effect), so the popular claim that BPC-157 ADDS to blood-thinner bleeding risk is unsupported and directionally backwards. However, this is a rodent-only signal: there are no human co-administration data, and this is NOT a clearance to combine BPC-157 with therapeutic anticoagulation. Because bleeding/clotting outcomes in anticoagulated patients are high-stakes, clinical caution and physician oversight remain appropriate; any protective effect in humans is unproven.

    Thromb Res 2011, PMID 21840572; PLoS One 2015, PMID 25897838, DOI 10.1371/journal.pone.0123454

  • Corticosteroids (methylprednisolone, prednisone)

    ProtectiveLow

    In animal models BPC-157 counteracts corticosteroid-impaired healing of burns, muscle, and other wounds, pointing to a counter-regulatory/protective rather than adverse interaction; no human data exist.

    Corticosteroid-impaired burn healing in burned mice, Burns 2003;29(4):323-34, PMID 12781609 (original 'J Physiol Paris 2001' label was incorrect); corticosteroid-impaired muscle healing (Sikiric group; exact Med Sci Monit 2010 citation not independently reconfirmed)

  • Alcohol (ethanol)

    ProtectiveLow

    BPC-157 prevents, attenuates, and reverses acute and chronic ethanol-induced gastric lesions and blunts intoxication/withdrawal in rodents via NO-dependent cytoprotection, indicating a protective interaction rather than a hazard (preclinical only).

    Ethanol-induced gastric lesions + blood pressure with L-NAME/L-arginine, Eur J Pharmacol 1997, PMID 9298922; chronic alcohol-drinking rats, J Physiol Paris 2001, PMID 11595453 (exact citation not independently reconfirmed)

  • TB-500 / Thymosin beta-4 (peptide co-administration)

    SynergisticTheoretical

    BPC-157 and TB-4 have complementary proposed mechanisms (BPC-157: VEGF/angiogenesis + microcirculation; TB-4: actin-driven cell migration), but no controlled study has tested them together, so synergy is inferred, not demonstrated. Their shared pro-angiogenic action is a theoretical concern where angiogenesis is undesirable (e.g., active or prior cancer).

    No primary combination study; individual mechanisms per Front Pharmacol 2021 review, DOI 10.3389/fphar.2021.627533; human-evidence gap per HSS J 2025 systematic review (35 preclinical / 1 clinical case series / 0 RCTs)

  • Nitric-oxide / vasoactive agents (nitrates, PDE5 inhibitors, antihypertensives, L-arginine)

    CautionTheoretical

    BPC-157 bidirectionally modulates the NO system - countering both L-NAME-induced hypertension and L-arginine-induced hypotension via an Src-caveolin-1-eNOS pathway - so an additive or offsetting effect on blood pressure/vascular tone with nitrates, PDE5 inhibitors, or antihypertensives is mechanistically plausible but has never been demonstrated clinically.

    NO / blood-pressure L-NAME/L-arginine study, Eur J Pharmacol 1997, PMID 9298922; Src-Cav1-eNOS pathway, Sci Rep 2020, DOI 10.1038/s41598-020-74022-y, PMID 33051481

  • Dopaminergic / serotonergic CNS agents (antipsychotics e.g. haloperidol, amphetamine, antidepressants)

    CautionTheoretical

    BPC-157 modulates dopaminergic and serotonergic signaling in rodents (e.g., counteracting haloperidol-induced catalepsy and amphetamine/apomorphine effects), a mechanistic basis for a possible pharmacodynamic interaction with antipsychotics or stimulants that has not been evaluated in humans.

    Haloperidol/L-NAME catalepsy work, Sikiric group (exact Prog Neuropsychopharmacol Biol Psychiatry 2020 citation not independently reconfirmed); reviewed in Front Pharmacol 2021, DOI 10.3389/fphar.2021.627533

  • CYP450-metabolized drugs (general small-molecule pharmacokinetic DDIs)

    NeutralLow

    As a 15-amino-acid peptide, BPC-157 is cleared by proteolysis to amino acids (half-life <30 min) with no evidence of cytochrome-P450 inhibition or induction, so classic pharmacokinetic drug-drug interactions are unlikely - an expected absence of interaction rather than a demonstrated safety signal.

    PK/distribution/metabolism/excretion in rats and dogs, Front Pharmacol 2022, PMC9794587, DOI 10.3389/fphar.2022.1026182

Known risks(5)

  • No large-scale human safety trials completed

  • Theoretical cancer risk — promotes angiogenesis (VEGFR2) which tumors use for growth

  • Limited human evidence, including older controlled studies reported as meeting abstracts

  • Named on WADA's Prohibited List since 2022

  • Unregulated products sold online vary widely in quality

Drug interactions(3)

  • TB-500

    Well-documented synergy for tissue repair. BPC-157 promotes angiogenesis while TB-500 modulates actin. Combined effect exceeds either alone.

  • GHK-Cu

    Both promote wound healing through different mechanisms. Emerging evidence of complementary tissue remodeling.

  • Semaglutide

    BPC-157 may support GI health during GLP-1 therapy. Different mechanisms.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
212
Human Studies
3

>95% evidence from animal studies. Human evidence includes three small full reports and older controlled studies available as meeting abstracts. Phase 2 RCT for hamstring strains began recruiting Feb 2026.

Researched for(8)

Rated by confidence in the evidence

  • Tendon healing and repair

    Medium

    Accelerates tendon fibroblast outgrowth and cell survival under oxidative stress

    Chang et al. 2011, J Appl Physiol 110:774-780, PMID 21148156; Staresinic et al. 2003, transected Achilles

  • Angiogenesis and vascular repair

    Medium

    Promotes new blood vessel formation through VEGFR2 activation

    Hsieh et al. 2017, J Mol Med (Berl) 95:323-333, PMID 27847966

  • Gastrointestinal cytoprotection

    Medium

    Protective effects against gastric ulcers and intestinal damage

    Vuksic et al. 2007, Surgery Today 37:768-777, PMID 17713731; PL-14736 (Pliva) Phase II UC program, unpublished

  • Musculoskeletal injury recovery

    Low

    Benefits in tendon ruptures, ligament tears, muscle detachment, bone healing

    Staresinic et al. 2006 (Novinscak co-author), J Orthop Res 24:1109-1117, transected quadriceps, PMID 16609979; muscle crush, Surgery Today 2008

  • Neuroprotection

    Low

    Protective in TBI, spinal cord compression, peripheral nerve transection models

    Rat spinal cord injury, PMID 35678659 / PMC9164058; TBI mouse studies

  • Anti-inflammatory effects

    Low

    Reduces inflammatory cytokines, downregulates NF-kB and Nos2

    Distant-organ I/R study, Medicina (Kaunas) 2025, PMC11857380; Sikiric group reviews

  • Interstitial cystitis symptom relief

    Speculative

    Pilot study: 10/12 patients complete symptom resolution

    Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (2024, n=12, uncontrolled; Jan 2023–Jun 2024)

  • Organ protection

    Low

    Protective effects across liver, heart, kidneys in preclinical studies

    Liver/kidney/lung I/R protection, Medicina (Kaunas) 2025, PMC11857380; superior mesenteric occlusion, PMC8229949

Benefits(8)

  • Tendon healing and repair

  • Angiogenesis and vascular repair

  • Gastrointestinal cytoprotection

  • Musculoskeletal injury recovery

  • Neuroprotection

  • Anti-inflammatory effects

  • Interstitial cystitis symptom relief

  • Organ protection

Key studies(5)

  1. Multiple authors

    HSS Journal

    2025

    Systematic review of 36 studies found BPC-157 enhances GH receptor expression and angiogenesis

  2. Lee E, Burgess K

    Altern Ther Health Med

    2025

    Two previously exposed adults reported no adverse effects during a short IV-infusion pilot; broader safety remains unestablished.

  3. Lee E, Walker C, Ayadi B

    Altern Ther Health Med

    2024

    10/12 women with IC had complete symptom resolution

  4. McGuire FP et al.

    Curr Rev Musculoskelet Med

    2025

    BPC-157 activates VEGFR2/Akt-eNOS; only 3 pilot studies in humans

  5. He L et al.

    Front Pharmacol

    2022

    Half-life <30min, ~14-19% IM bioavailability in rats, ~45-51% in dogs

What research suggests over time

  • Weeks 2-4

    Practitioner-reported

    Reduced soft-tissue pain and improved range of motion at injury sites in user reports; preclinical models show angiogenesis upregulation within days.

  • Months 2-3

    Preclinical (rat/mouse)

    Tendon and ligament functional improvement in animal models (Staresinic Achilles model); subjective gut symptom improvements common.

  • Long-term

    Preclinical only

    Sustained tissue repair effects in animal studies; no validated human long-term timeline. FDA placed it in compounding Category 2 in September 2023; in a draft interim policy posted October 28, 2026 and open for public comment until mid-November, HHS said it does not intend to act against limited compounding under conditions.

Regulation & availability

Why researchers look at it

Over 200 animal studies show remarkably consistent healing of tendons, ligaments, muscles, and gut tissue, but human clinical data are only now emerging, with earlier randomized studies reported only in limited abstracts. It is unusually stable in stomach acid, making it one of the few peptides that can be taken orally.

Estimated cost
No approved product and no verified reference price
FDA status
BPC-157 is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound BPC-157 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection (under the skin or into muscle), oral or topical product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing BPC-157; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records. A Phase 2 randomized trial (NCT07437547) began in February 2026. WADA's 2026 Prohibited List names it as a non-approved substance (S0), prohibited at all times.
WADA status
Banned — S0 category (non-approved substances); named on WADA's Prohibited List since 2022
Prescribability
BPC-157 is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound BPC-157 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection (under the skin or into muscle), oral or topical product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing BPC-157; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
Availability
BPC-157 is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound BPC-157 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection (under the skin or into muscle), oral or topical product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing BPC-157; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.

International status

  • EU

    Not approved

  • UK

    Not approved

  • US

    BPC-157 is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound BPC-157 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection (under the skin or into muscle), oral or topical product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing BPC-157; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.

  • Canada

    Not approved. A May 2026 Health Canada notice lists a recall of unauthorized BPC-157 APIs supplied to compounding and community pharmacies.

  • Australia

    Schedule 4 (prescription only) via compounding

Regulatory timeline(7)

  1. 2015
    Phase I trial registeredNCT02637284 (Bepecin) — 42 healthy volunteers. Never published results.
  2. 2022
    Named on WADA's Prohibited ListNamed as an example of a non-approved substance (S0) on the 2022 List, the first substance S0 names
  3. 2023-09
    FDA Category 2Restricted from compounding pharmacies
  4. 2026-02
    Phase 2 RCT beginsNCT07437547 for hamstring strains; earlier controlled human studies exist.
  5. 2026-04
    Removed from Category 2 after nominations withdrawnFDA moved BPC-157 to its table of nominated-but-withdrawn substances; the withdrawal was not an FDA safety finding.
  6. 2026-07-23
    FDA advisory committee discusses BPC-157; no rule yetFDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 (free base and acetate) for ulcerative colitis. FDA's drug reviewers recommended against listing it and the committee voted in favor, as HHS's October 2026 policy records; FDA has not posted minutes or changed the list.
  7. 2026-10-28
    HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of BPC-157 acetate under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.

Sources & FAQs

Research sources(5)

Frequently asked questions(4)

Is BPC-157 safe?

Human data are limited. Adverse events have been reported, although causality is uncertain. Theoretical cancer concern due to angiogenesis promotion. Risk cannot be fully characterized.

Can I legally obtain BPC-157 in the US in 2026?

BPC-157 is not FDA-approved, and it is not a lawful dietary-supplement ingredient. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound BPC-157 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection (under the skin or into muscle), oral or topical product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. It is not on FDA's compounding list, and unregulated products sold online are outside the policy. WADA prohibits BPC-157 at all times.

How is it administered?

Subcutaneous injection (most common), IM, IV, or oral. Stable in gastric juice >24h. Half-life under 30 min injectable.

Does BPC-157 promote cancer?

Theoretical concern due to angiogenesis. Not directly studied. No cancer cases attributed to it. Warrants further investigation.